Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open, Single-arm, Single-dose, Phase I/II Study Evaluating the Safety, Tolerability, and Efficacy of LY-M003 Injection in Adult Patients With Wilson's Disease

NCT07641140 is registered in ClinicalTrials.gov with Lingyi Biotech Co., Ltd. as lead sponsor.

NCT NCT07641140
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07641140 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open, Single-arm, Single-dose, Phase I/II Study Evaluating the Safety, Tolerability, and Efficacy of LY-M003 Injection in Adult Patients With Wilson's Disease
Lead sponsor
Lingyi Biotech Co., Ltd.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
June 15, 2026
Completion date
December 30, 2032
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

wilson's disease